ASBP

ESTERO, FL / ACCESS Newswire / August 13, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), today announced that management will be present and host one-on-one meetings with investors at Sidoti & Company's Micro-Cap Virtual Investor Conference taking place on August 19-20, 2026. Management plans to discuss its clinical and commercial development pipeline and its recently closed acquisition of Dura Driver Control Systems, a leading global automotive supplier with a 100+ year history and $200M+ in 2025 revenue.

Acquisition represents a transformative milestone for Aspire, positioning the Company to rapidly evolve into a diversified, high-revenue enterprise Adds an established global brand with scale in large and growing markets driven by trends in vehicle and mobility control systems Augments revenue growth profile and diversifies Aspires' development and commercial portfolio with new high growth business Expected to immediately improve path to profitability ESTERO, FL / ACCESS Newswire / August 10, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), today announced that, the Company has completed its previously announced acquisition (the "Acquisition") of Dura Driver Control Systems ("DCS"), a tier-one supplier specializing in automotive systems that facilitate electronic driver control and the migration toward vehicle electrification, safety, lightweighting, and sustainability. The acquisition is expected to enhance Aspire's ability to deliver increased revenues, durable earnings and cash flow, driven by a new portfolio of product offerings in the large and growing markets for vehicle and mobility control systems.

High-Octane Partnership: Multi-time X Games medalist Jarryd McNeil joins BUZZ BOMB™ to fuel brand expansion in action sports. Consumer Connection: The collaboration strengthens BUZZ BOMB™'s commitment to delivering fast-acting energy to elite athletes and active consumers worldwide.

The brand expands nationwide distribution on Amazon, delivering a waterless, rapid-dissolve 50 mg caffeine powder built for active, on-the-go lifestyles. ESTERO, FL / ACCESS Newswire / June 24, 2026 / Aspire Biopharma Holdings, Inc.'s (Nasdaq:ASBP) ("Aspire" or the "Company") wholly owned subsidiary Buzz Bomb Caffeine Company LC today announced the nationwide Amazon launch of its innovative BUZZ BOMB™ 50mg caffeine stick packs.

ESTERO, Fla., June 17, 2026 (GLOBE NEWSWIRE) -- Aspire Biopharma Holdings, Inc.'s (Nasdaq: ASBP) (“Aspire” or the “Company”), today announced that it will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on June 25th, 2026.

Aspire Biopharma Holdings Inc. (NASDAQ:ASBP) shares initially surged on Friday but have since reversed. Here's what you need to know.

ESTERO, FL / ACCESS Newswire / May 28, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today issued the following letter to shareholders from Chief Executive Officer Kraig Higginson. Dear Fellow Shareholders, 2026 is shaping up to be a defining year for Aspire Biopharma Holdings.

ESTERO, FL / ACCESS Newswire / May 27, 2026 / Aspire Biopharma Holdings, Inc.'s (Nasdaq:ASBP) ("Aspire" or the "Company") wholly owned subsidiary Buzz Bomb Caffeine Company LC is proud to announce a strategic partnership with EoS Fitness, the High Value. Low Price.

ESTERO, FL / ACCESS Newswire / May 7, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that it will effect a one-for-thirty (1:30) reverse stock split (the "reverse split") of its common stock, par value $0.0001 per share (the "Common Stock"), that will become effective on May 11, 2026, at 12:01 AM Eastern Time, before the opening of trading on The Nasdaq Capital Market ("Nasdaq"). Aspire has requested that its Common Stock begin trading on May 11, 2026, on a post-reverse split basis on the Nasdaq under the existing symbol "ASBP".

ESTERO, FL / ACCESS Newswire / April 27, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced that its Board of Directors (the "Board") has authorized the repurchase of up to $5.0 million of the Company's common stock. The authorization reflects the Board's confidence in the Company's balance sheet strength, the value of its drug development pipeline and supplement business, and the potential value creation from the recently announced Binding Letter of Intent (LOI) to acquire Dura Driver Control Systems (DCS).